stockrow
Saturday 7 November 2026
Export OCGN’s income statement to Excel — free account
Ocugen, Inc.
OCGN Healthcare Biotechnology
Ocugen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.4 million, up 8.83% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +84.9%
- Free cash flow
- −22.2%
- Total debt
- −93.7%
Quarter to September 2026, against a year earlier
0.93
0.11
+13.41%
Follow OCGN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 2 | 3 | 3 |
| (776.89%) | (660.00%) | 1,211.66% | 923.92% | ||
| (107.73%) | (118.11%) | (92.03%) | (78.91%) | ||
ROIC |
0.00% | (1,317.07%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(432.44%) | (226.29%) | 628.74% | 442.71% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.19) | (0.18) | (0.18) | (0.19) | |
Free Cash Flow |
(57.15) | (59.58) | (61.02) | (63.90) | |
Capital Expenditures |
(0.18) | (0.17) | (0.15) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(162.37%) | (89.11%) | (71.59%) | (93.49%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
900.75% | 928.91% | 955.55% | 944.03% | |
Selling, General and Administrative Expense of Revenue |
624.95% | 654.94% | 648.89% | 600.44% | |
Share Based Compensation of Revenue |
174.64% | 206.49% | 201.05% | 192.26% | |
Interest Coverage |
(12.13) | (12.62) | (8.16) | (6.76) | |
Operating CF/Net income |
0.84 | 0.83 | 0.74 | 0.97 | |
Depreciation/Fixed assets |
0.26 | 0.28 | 0.40 | 0.45 | |
Capex/Depreciation |
(0.05) | (0.05) | (0.03) | (0.04) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.19) | (0.18) | (0.18) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.04 |
Columns are period end dates · fundamentals updated 6 Nov 2026